SHH and cancer: These dual inhibitory HS roles in Hh biology may open exciting avenues for the generation of Shh-tailored polysaccharide-based cancer therapeutics that, in contrast to 5E1 or robotnikin, can also act on the non-released inactive precursor at the cell surface.